ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
MSD’s Keytruda approved for liver cancer
November 14, 2018US regulators have expanded the use of MSD’s anti-PD-1 therapy Keytruda to include treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. -
OncoSec Announces Positive Data from Trial of ImmunoPulse IL-12, Pembrolizumab
November 09, 2017The updated clinical and correlative immune-focused biomarker data demonstrated a 57% progression free survival (PFS) rate at 15 months with 100% (11/11) duration of response and median PFS not yet reached.
Pharma Sources Insight January 2025
